Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis

NCT06947993 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

224

Enrollment

INDUSTRY

Sponsor class

Conditions

Atopic Dermatitis

Interventions

DRUG: GHZ339
DRUG: Placebo

Sponsor

Novartis Pharmaceuticals